Pinnacle Medicines | $89,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
Mirage | $75,000,000 | (Mar 27, 2026)
Phase Genomics
United States
- Seattle, Washington
- 06/03/2024
- Unknown
- $1,500,000
Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples as well as industry-leading genome and metagenome assembly and analysis software.
Founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs, the company’s mission is to empower scientists with state-of-the-art genomic tools that will accelerate breakthrough discoveries. The company serves academic and commercial researchers in diverse fields and industries.
- Industry Biotechnology Research
- Website https://phasegenomics.com/
- LinkedIn https://www.linkedin.com/company/phase-genomics-inc/
Related People
Ivan Liachko 🇺🇦Co Founder
United States -
Seattle, Washington
A molecular geneticist/genomicist with over two decades of experience in wet-lab and computational biology. Founder and CEO of Seattle-based Phase Genomics Inc. (est. 2015). Passionate about applying genomic technology to improve our world and mentoring scientists interested in commercialization.
**Citations on Google Scholar*: https://scholar.google.com/citations?user=VBQJ1-gAAAAJ&hl=en
**Other Publications & News*: https://phasegenomics.com/publications/
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)
Payy | $6,000,000 | (Mar 27, 2026)
Conntour | $7,000,000 | (Mar 27, 2026)
KilgourMD | Undisclosed Amount | (Mar 27, 2026)
Terrestrial | $50,000,000 | (Mar 27, 2026)
Krane | $9,000,000 | (Mar 26, 2026)
Zalos (YC F25) | $3,600,000 | (Mar 26, 2026)